1
|
Olfson E, Hartz S, Carere DA, Green RC, Roberts JS, Bierut LJ. Implications of Personal Genomic Testing for Health Behaviors: The Case of Smoking. Nicotine Tob Res 2016; 18:2273-2277. [PMID: 27613923 DOI: 10.1093/ntr/ntw168] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Accepted: 06/27/2016] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Direct-to-consumer personal genomic testing has the potential to influence health behaviors, including smoking. Critics of this testing highlight limited evidence to support positive behavioral benefits and caution that genomic results may provide false reassurance, leading to unhealthy behaviors. This study investigates interest in genetic risks of smoking-related diseases and changes in smoking behaviors among genomic testing consumers. METHODS From 2012 to 2013, a longitudinal series of web surveys was conducted. A total of 1464 customers of 23andMe and Pathway Genomics completed a survey prior to viewing genomic test results, of which 1002 participants provided data on smoking behaviors 6 months after receiving results. RESULTS At baseline, 64% of participants were never smokers, 29% were former smokers, and 7% were current smokers. Most baseline current smokers were very interested in genetic risk results for lung cancer (65%) and heart disease (72%). For lung cancer, this interest was significantly greater than former (50% very interested) and never smokers (37% very interested) (p < .0001). Even though participants were interested in smoking-related disease genetic risks, 96% reported the same smoking status at baseline and 6-month follow-up. Importantly, only 1% (n = 13/916) of former and never smokers became current smokers at 6 months and 22% (n = 14/64) of current smokers reported quitting. CONCLUSIONS Overall, smokers show a high level of interest in genetic risks of smoking-related illnesses. The experience of receiving direct-to-consumer genomic health risks does not appear to have obvious harms related to smoking behaviors, with some potential benefits. IMPLICATIONS In the setting of ongoing controversy surrounding direct-to-consumer genomic testing, this study provides evidence that consumers are interested in genetic risk results of smoking-related diseases. Receiving genomic testing results does not lead to smoking initiation among never smokers or reinitiation among former smokers and may be associated with a higher quit rate among current smokers at 6-month follow-up than the general population. These findings ease concerns that direct-to-consumer genomic testing could lead to false reassurance and unhealthy behaviors related to smoking.
Collapse
Affiliation(s)
- Emily Olfson
- Child Study Center and Department of Psychiatry, Yale University School of Medicine, New Haven, CT
| | - Sarah Hartz
- Department of Psychiatry, Washington University School of Medicine, St Louis, MO
| | - Deanna Alexis Carere
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| | | | - J Scott Roberts
- Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI
| | - Laura J Bierut
- Department of Psychiatry, Washington University School of Medicine, St Louis, MO;
| | | |
Collapse
|
2
|
Arribas-Ayllon M. Genetic testing and human subjectivity. SOCIAL AND PERSONALITY PSYCHOLOGY COMPASS 2015. [DOI: 10.1111/spc3.12174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Dorsey ER, Darwin KC, Mohammed S, Donohue S, Tethal A, Achey MA, Ward S, Caughey E, Conley ED, Eriksson N, Ravina B. Virtual research visits and direct-to-consumer genetic testing in Parkinson's disease. Digit Health 2015; 1:2055207615592998. [PMID: 29942542 PMCID: PMC5999055 DOI: 10.1177/2055207615592998] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
OBJECTIVE The purpose of this study was to conduct a proof-of-concept study to evaluate remote recruitment and assessment of individuals ("virtual research visits") with Parkinson's disease who have pursued direct-to-consumer genetic testing. METHODS Participants in 23andMe's "Parkinson's Research Community" were contacted by 23andMe. Fifty willing participants living in 23 states underwent a remote, standardized assessment including cognitive and motor tests by a neurologist via video conferencing and then completed a survey. Primary outcomes assessed were (a) proportion of participants who completed the remote assessments; (b) level of agreement (using Cohen's kappa coefficient) of patient-reported data with that of a neurologist; and (c) interest in future virtual research visits. RESULTS The self-reported diagnosis of Parkinson's disease was confirmed in all cases (k = 1.00). The level of agreement for age of symptom onset (k = 0.97) and family history (k = 0.85) was very good but worse for falling (k = 0.59), tremor (k = 0.56), light-headedness (k = 0.31), and urine control (k = 0.15). Thirty-eight (76%) of the 50 participants completed a post-assessment survey, and 87% of respondents said they would be more or much more willing to participate in future clinical trials if they could do research visits remotely. CONCLUSION Remote clinical assessments of individuals with known genotypes were conducted nationally and rapidly from a single site, confirmed self-reported diagnosis, and were received favorably. Direct-to-consumer genetic testing and virtual research visits together may enable characterization of genotype and phenotype for geographically diverse populations.
Collapse
Affiliation(s)
- E Ray Dorsey
- Center for Human Experimental
Therapeutics, University of Rochester, USA
- Department of Neurology, University of
Rochester Medical Center, USA
| | | | | | | | | | - Meredith A Achey
- Center for Human Experimental
Therapeutics, University of Rochester, USA
| | - Susan Ward
- Voyager Therapeutics, 75 Sidney Street,
Cambridge, MA 02139, USA
| | - Elaine Caughey
- Voyager Therapeutics, 75 Sidney Street,
Cambridge, MA 02139, USA
| | | | | | - Bernard Ravina
- Voyager Therapeutics, 75 Sidney Street,
Cambridge, MA 02139, USA
| |
Collapse
|
4
|
Return of individual genetic results in a high-risk sample: enthusiasm and positive behavioral change. Genet Med 2014; 17:374-9. [PMID: 25166427 PMCID: PMC4344933 DOI: 10.1038/gim.2014.110] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2014] [Accepted: 07/15/2014] [Indexed: 11/16/2022] Open
Abstract
Purpose The goal of this study is to examine participant responses to disclosure of genetic results in a minority population at high-risk for depression and anxiety. Methods 82 subjects in a genetic study of nicotine dependence were offered personalized genetic results: all were nicotine dependent and 64% self-identified as African American. Pathway Genomics was used to evaluate genetic risks for 5 complex diseases. Participants returned 4–8 weeks following enrollment for in-person genetic counseling interviews and evaluation of baseline measures. A telephone follow-up was performed 4–8 weeks later to assess responses to results. Results 50 of the 82 subjects (61%) were interested in receiving genetic results. These participants had multiple risk factors, including high baseline measures of depression (66%) and anxiety (32%), as well as low rates of employment (46%), adequate health literacy (46%), and health insurance (45%). Pathway Genomics reported “increased risk” for at least one disease in 77% of subjects. 95% of participants reported that they appreciated the genetic results, and receiving these results was not associated with changes in symptoms of depression or anxiety. Furthermore, after return of genetic results, smoking cessation attempts increased (p=0.003). Conclusion Even in an underserved population at high-risk for adverse psychological reactions, subjects responded positively to personalized genetic results.
Collapse
|
5
|
Variations in predicted risks in personal genome testing for common complex diseases. Genet Med 2013; 16:85-91. [PMID: 23807614 DOI: 10.1038/gim.2013.80] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Accepted: 04/18/2013] [Indexed: 11/08/2022] Open
Abstract
PURPOSE The promise of personalized genomics for common complex diseases depends, in part, on the ability to predict genetic risks on the basis of single nucleotide polymorphisms. We examined and compared the methods of three companies (23andMe, deCODEme, and Navigenics) that have offered direct-to-consumer personal genome testing. METHODS We simulated genotype data for 100,000 individuals on the basis of published genotype frequencies and predicted disease risks using the methods of the companies. Predictive ability for six diseases was assessed by the AUC. RESULTS AUC values differed among the diseases and among the companies. The highest values of the AUC were observed for age-related macular degeneration, celiac disease, and Crohn disease. The largest difference among the companies was found for celiac disease: the AUC was 0.73 for 23andMe and 0.82 for deCODEme. Predicted risks differed substantially among the companies as a result of differences in the sets of single nucleotide polymorphisms selected and the average population risks selected by the companies, and in the formulas used for the calculation of risks. CONCLUSION Future efforts to design predictive models for the genomics of common complex diseases may benefit from understanding the strengths and limitations of the predictive algorithms designed by these early companies.
Collapse
|
6
|
Vayena E, Gourna E, Streuli J, Hafen E, Prainsack B. Experiences of early users of direct-to-consumer genomics in Switzerland: an exploratory study. Public Health Genomics 2012; 15:352-62. [PMID: 23154382 DOI: 10.1159/000343792] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Accepted: 09/24/2012] [Indexed: 11/19/2022] Open
Abstract
AIMS This study explores attitudes, motivations and self-reported impact in connection with direct-to-consumer (DTC) genomic testing amongst a group of life scientists in Switzerland. METHODS Data were collected through: (1) a self-completion online questionnaire, and (2) semi-structured qualitative interviews. Forty participants completed the questionnaire and 10 were interviewed. RESULTS Curiosity was mentioned as the primary reason for undergoing testing, while less significance was attributed to receiving actionable health information. The opportunity to contribute to research ranked high as a motive for testing. Overall, participants assessed their experience with the test as positive and were willing to recommend it to others. Some reported that the testing had an impact on how they view their health, but only a third of participants planned on showing the results to health practitioners. Participants consistently referred to 'fun' when describing several aspects of the testing experience. The 'fun factor' manifested itself in different phases of the process, including the motivation for taking the test, receiving the information and putting the test results to use (including sharing and discussing it with others). This finding suggests the need to further explore the concept of personal utility in DTC genomics. CONCLUSIONS Although this group is not representative of the broader population due to both their scientific expertise and their willingness to try out a controversial new technology, their experiences provide valuable insights into the role of personal curiosity and altruism (fostering medical research) as motivations for testing and the utility attributed to both.
Collapse
Affiliation(s)
- E Vayena
- Institute of Biomedical Ethics, University of Zurich, Zurich, Switzerland.
| | | | | | | | | |
Collapse
|
7
|
Finney Rutten LJ, Gollust SE, Naveed S, Moser RP. Increasing Public Awareness of Direct-to-Consumer Genetic Tests: Health Care Access, Internet Use, and Population Density Correlates. J Cancer Epidemiol 2012; 2012:309109. [PMID: 22899921 PMCID: PMC3413952 DOI: 10.1155/2012/309109] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2012] [Revised: 06/19/2012] [Accepted: 06/19/2012] [Indexed: 11/18/2022] Open
Abstract
Uncertainty around the value of and appropriate regulatory models for direct-to-consumer (DTC) genetic testing underscores the importance of tracking public awareness of these services. We analyzed nationally representative, cross-sectional data from the Health Information National Trends Survey in 2008 (n = 7, 674) and 2011 (n = 3, 959) to assess population-level changes in awareness of DTC genetic testing in the U.S. and to explore sociodemographic, health care, Internet use, and population density correlates. Overall, awareness increased significantly from 29% in 2008 to 37% in 2011. The observed increase in awareness from 2008 to 2011 remained significant (OR = 1.39) even when adjusted for sociodemographic variables, health care access, Internet use, and population density. Independent of survey year, the odds of awareness of DTC genetic tests were significantly higher for those aged 50-64 (OR = 1.64), and 65-74 (OR = 1.60); college graduates (OR = 2.02); those with a regular source of health care (OR = 1.27); those with a prior cancer diagnosis (OR = 1.24); those who use the Internet (OR = 1.27); and those living in urban areas (OR = 1.25). Surveillance of awareness-along with empirical data on use of and response to genetic risk information-can inform public health and policy efforts to maximize benefits and minimize risks of DTC genetic testing.
Collapse
Affiliation(s)
- Lila J. Finney Rutten
- Clinical Monitoring Research Program, SAIC-Frederick, Inc., NCI, Frederick, MD 21702, USA
| | - Sarah E. Gollust
- Division of Health Policy and Management, University of Minnesota, 420 Delaware Street SE, MMC 729, Minneapolis, MN 55455, USA
| | - Sana Naveed
- Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Boulvard, MSC 7326, Bethesda, MD 20892, USA
| | - Richard P. Moser
- Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Boulvard, MSC 7326, Bethesda, MD 20892, USA
| |
Collapse
|
8
|
Lehmann LS, Kaufman DJ, Sharp RR, Moreno TA, Mountain JL, Roberts JS, Green RC. Navigating a research partnership between academia and industry to assess the impact of personalized genetic testing. Genet Med 2012; 14:268-73. [PMID: 22241103 DOI: 10.1038/gim.2011.59] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
PURPOSE To describe the process of structuring a partnership between academic researchers and two personalized genetic testing companies that would manage conflicts of interest while allowing researchers to study the impact of this nascent industry. METHODS We developed a transparent process of ongoing communication about the interests of all research partners to address challenges in establishing study goals, survey development, data collection, analysis, and manuscript preparation. Using the existing literature on conflicts of interest and our experience, we created a checklist for academic and industry researchers seeking to structure research partnerships. RESULTS Our checklist includes questions about the risk to research participants, sponsorship of the study, control of data analysis, freedom to publish results, the impact of the research on industry customers, openness to input from all partners, sharing results before publication, and publication of industry-specific data. Transparency is critical to building trust between partners. Involving all partners in the research development enhanced the quality of our research and provided an opportunity to manage conflicts early in the research process. CONCLUSION Navigating relationships between academia and industry is complex and requires strategies that are transparent and responsive to the concerns of all. Employing a checklist of questions prior to beginning a research partnership may help to manage conflicts of interest.
Collapse
Affiliation(s)
- Lisa Soleymani Lehmann
- Department of Medicine and Center for Bioethics, Brigham and Women's Hospital, Boston, Massachusetts, USA.
| | | | | | | | | | | | | |
Collapse
|
9
|
Myers MF. Health care providers and direct-to-consumer access and advertising of genetic testing in the United States. Genome Med 2011; 3:81. [PMID: 22204616 PMCID: PMC3334546 DOI: 10.1186/gm297] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Marketing pressures, regulatory policies, clinical guidelines, and consumer demand all affect health care providers' knowledge and use of health-related genetic tests that are sold and/or advertised to consumers. In addition, clinical guidelines, regulatory policies, and educational efforts are needed to promote the informed use of genetic tests that are sold and advertised to consumers and health care providers. A shift in culture regarding the regulation of genetic tests that are sold directly to consumers is suggested: by recent actions taken by the US Food and Drug Administration (FDA), including letters sent to direct-to-consumer (DTC) genetic testing companies stating that their tests meet the definition of medical devices; by public meetings held by the FDA to discuss laboratory developed tests; and by the convening of the Molecular and Clinical Genetics Panel to gather input on scientific issues concerning DTC genetic tests that make medical claims. This review provides a brief overview of DTC advertising and the regulation of pharmaceuticals and genetic tests in the United States. It highlights recent changes in the regulatory culture regarding genetic tests that are sold to consumers, and discusses the impact on health care providers of selling and advertising genetic tests directly to consumers.
Collapse
Affiliation(s)
- Melanie F Myers
- Genetic Counseling Graduate Program, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Burnet Avenue, Cincinnati, OH 45229, USA.
| |
Collapse
|
10
|
James KM, Cowl CT, Tilburt JC, Sinicrope PS, Robinson ME, Frimannsdottir KR, Tiedje K, Koenig BA. Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. Mayo Clin Proc 2011; 86:933-40. [PMID: 21964170 PMCID: PMC3184022 DOI: 10.4065/mcp.2011.0190] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To assess the impact of direct-to-consumer (DTC) predictive genomic risk information on perceived risk and worry in the context of routine clinical care. PATIENTS AND METHODS Patients attending a preventive medicine clinic between June 1 and December 18, 2009, were randomly assigned to receive either genomic risk information from a DTC product plus usual care (n=74) or usual care alone (n=76). At intervals of 1 week and 1 year after their clinic visit, participants completed surveys containing validated measures of risk perception and levels of worry associated with the 12 conditions assessed by the DTC product. RESULTS Of 345 patients approached, 150 (43%) agreed to participate, 64 (19%) refused, and 131 (38%) did not respond. Compared with those receiving usual care, participants who received genomic risk information initially rated their risk as higher for 4 conditions (abdominal aneurysm [P=.001], Graves disease [P=.04], obesity [P=.01], and osteoarthritis [P=.04]) and lower for one (prostate cancer [P=.02]). Although differences were not significant, they also reported higher levels of worry for 7 conditions and lower levels for 5 others. At 1 year, there were no significant differences between groups. CONCLUSION Predictive genomic risk information modestly influences risk perception and worry. The extent and direction of this influence may depend on the condition being tested and its baseline prominence in preventive health care and may attenuate with time.
Collapse
|
11
|
Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issues. BMC Med Ethics 2011; 12:11. [PMID: 21672210 PMCID: PMC3141793 DOI: 10.1186/1472-6939-12-11] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2011] [Accepted: 06/14/2011] [Indexed: 11/26/2022] Open
Abstract
Background As genetics technology proceeds, practices of genetic testing have become more heterogeneous: many different types of tests are finding their way to the public in different settings and for a variety of purposes. This diversification is relevant to the discourse on ethical, legal and societal issues (ELSI) surrounding genetic testing, which must evolve to encompass these differences. One important development is the rise of personal genome testing on the basis of genetic profiling: the testing of multiple genetic variants simultaneously for the prediction of common multifactorial diseases. Currently, an increasing number of companies are offering personal genome tests directly to consumers and are spurring ELSI-discussions, which stand in need of clarification. This paper presents a systematic approach to the ELSI-evaluation of personal genome testing for multifactorial diseases along the lines of its test characteristics. Discussion This paper addresses four test characteristics of personal genome testing: its being a non-targeted type of testing, its high analytical validity, low clinical validity and problematic clinical utility. These characteristics raise their own specific ELSI, for example: non-targeted genetic profiling poses serious problems for information provision and informed consent. Questions about the quantity and quality of the necessary information, as well as about moral responsibilities with regard to the provision of information are therefore becoming central themes within ELSI-discussions of personal genome testing. Further, the current low level of clinical validity of genetic profiles raises questions concerning societal risks and regulatory requirements, whereas simultaneously it causes traditional ELSI-issues of clinical genetics, such as psychological and health risks, discrimination, and stigmatization, to lose part of their relevance. Also, classic notions of clinical utility are challenged by the newer notion of 'personal utility.' Summary Consideration of test characteristics is essential to any valuable discourse on the ELSI of personal genome testing for multifactorial diseases. Four key characteristics of the test - targeted/non-targeted testing, analytical validity, clinical validity and clinical utility - together determine the applicability and the relevance of ELSI to specific tests. The paper identifies and discusses four areas of interest for the ELSI-debate on personal genome testing: informational problems, risks, regulatory issues, and the notion of personal utility.
Collapse
|
12
|
Lynch J, Parrott A, Hopkin RJ, Myers M. Media coverage of direct-to-consumer genetic testing. J Genet Couns 2011; 20:486-94. [PMID: 21638197 DOI: 10.1007/s10897-011-9374-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2010] [Accepted: 05/05/2011] [Indexed: 10/18/2022]
Abstract
Media coverage of Direct-to-Consumer (DTC) genetic testing shapes public perception of such testing. The purpose of this study was to determine and assess the themes presented by U.S. news media regarding DTC genetic testing. We performed a Lexis-Nexis search with the keywords "Direct-to-Consumer" and "genetic test" for news stories published from 2006-2009. The sample was coded on themes of genetic determinism, privacy, discrimination, validity, regulation, the Genetic Information Nondiscrimination Act (GINA), utility, and cost. Ninety-two news stories were included. Stories displayed moderate genetic determinism and were neutral about validity and utility. Stories indicated that insurance and employers were the most likely sources of discrimination, yet identified the physicians and DTC companies as groups most likely to violate privacy. Stories claimed lack of regulation would harm consumers, but most post-GINA stories did not discuss the law. The costs of tests were frequently included. The results of this study show a broad range of views toward DTC genetic testing and its potential impacts. The genetics community should be aware that the public has been exposed to multiple views of DTC genetic testing when discussing these tests.
Collapse
Affiliation(s)
- John Lynch
- Department of Communication, University of Cincinnati, Cincinnati, OH 45221-0184, USA.
| | | | | | | |
Collapse
|
13
|
|
14
|
O'Neill SC, McBride CM, Alford SH, Kaphingst KA. Preferences for genetic and behavioral health information: the impact of risk factors and disease attributions. Ann Behav Med 2010; 40:127-37. [PMID: 20532842 PMCID: PMC3498951 DOI: 10.1007/s12160-010-9197-1] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Increased availability of genetic risk information may lead the public to give precedence to genetic causation over behavioral/environmental factors, decreasing motivation for behavior change. Few population-based data inform these concerns. We assess the association of family history, behavioral risks, and causal attributions for diseases and the perceived value of pursuing information emphasizing health habits or genes. 1,959 healthy adults completed a survey that assessed behavioral risk factors, family history, causal attributions of eight diseases, and health information preferences. Participants' causal beliefs favored health behaviors over genetics. Interest in behavioral information was higher than in genetic information. As behavioral risk factors increased, inclination toward genetic explanations increased; interest in how health habits affect disease risk decreased. Those at greatest need for behavior change may hold attributions that diminish interest in information for behavior change. Enhancing understanding of gene-environment influences could be explored to increase engagement with health information.
Collapse
Affiliation(s)
- Suzanne C O'Neill
- Social and Behavioral Research Branch, National Human Genome Research Institute/National Institutes of Health (NHGRI/NIH), Bethesda, MD, USA.
| | | | | | | |
Collapse
|
15
|
Thrush SA, McCaffrey R. Direct-to-Consumer Genetic Testing: What the Nurse Practitioner Should Know. J Nurse Pract 2010. [DOI: 10.1016/j.nurpra.2009.10.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
16
|
Mihaescu R, van Hoek M, Sijbrands EJG, Uitterlinden AG, Witteman JCM, Hofman A, van Duijn CM, Janssens ACJW. Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med 2010; 11:588-94. [PMID: 19636253 DOI: 10.1097/gim.0b013e3181b13a4f] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE Commercial internet-based companies offer genome-wide scans to predict the risk of common diseases and personalize nutrition and lifestyle recommendations. These risk estimates are updated with every new gene discovery. METHODS To assess the benefits of updating risk information in commercial genome-wide scans, we compared type 2 diabetes risk predictions based on TCF7L2 alone, 18 polymorphisms alone, and 18 polymorphisms plus age, sex, and body mass index. Analyses were performed using data from the Rotterdam study, a prospective, population-based study among individuals aged 55 years and older. Data were available from 5297 participants. RESULTS The actual prevalence of type 2 diabetes in the study population was 20%. Predicted risks were below average for carriers of the TCF7L2 CC genotype (predicted risk 17.6%) and above average for the CT and TT genotypes (20.8% and 28.0%). Adding the other 17 polymorphisms caused 34% of participants to be reclassified (i.e., switched between below and above average): 24% of the CC carriers changed to increased risk, 52% and 6% of the CT and TT carriers changed to decreased risk. Including information on age, sex, and body mass index caused 29% to change categories (27%, 31%, and 19% for CC, CT, and TT carriers, respectively). In total, 39% of participants changed categories once when risk factors were updated, and 11% changed twice, i.e., back to their initial risk category. CONCLUSION Updating risk factors may produce contradictory information about an individual's risk status over time, which is undesirable if lifestyle and nutritional recommendations vary accordingly.
Collapse
Affiliation(s)
- Raluca Mihaescu
- Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
The advent of both population genomic studies and direct-to-consumer personal genetic testing raises ethical challenges for researchers and physicians alike. Quality and solidarity can now be added to traditional ethical principles, such as autonomy and privacy. There is no doubt that genetic information is going 'public'. Informatic technologies allow for greater accessibility and integration, but can researchers and physicians handle the challenges? Are ethics committees equipped to handle this shift towards greater openness and towards a conflation of research and traditional medical ethics?
Collapse
Affiliation(s)
- Bartha Maria Knoppers
- Centre of Genomics and Policy, McGill University and Genome Quebec Innovation Centre, 740 Dr. Penfield Ave, Room 5210, Montreal H3A 1A4, Quebec, Canada.
| | - Denise Avard
- Centre of Genomics and Policy, McGill University and Genome Quebec Innovation Centre, 740 Dr. Penfield Ave, Room 5210, Montreal H3A 1A4, Quebec, Canada.
| |
Collapse
|
18
|
Collier DA, Vassos E, Holden S, Patch C, McGuire P, Lewis C. Advances in the genetics of schizophrenia: will high-risk copy number variants be useful in clinical genetics or diagnostics? F1000 MEDICINE REPORTS 2009; 1. [PMID: 20948719 PMCID: PMC2948301 DOI: 10.3410/m1-61] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Schizophrenia is a highly heritable, common mental illness, affecting 1% of the population worldwide. It is currently diagnosed using exclusive clinical criteria, and at present there are no genetic tests to facilitate this process. There are also no reliable means to predict who will develop the disease in later life. Genetic counselling uses crude estimates of risk based on family history, as the strongest predictive factor is having an affected first-degree relative. It has recently become apparent that large de novo deletions in the genome (copy number variants, or CNVs) can increase risk of the disease by tenfold or more. The purpose of this report is to assess whether these ‘high risk’ pathogenic CNVs might be useful in a clinical genetic or diagnostic setting. Routine use of laboratory techniques such as comparative genome hybridisation will reveal these de novo CNVs in standard investigative procedures for referrals to clinical genetics. The lack of disease specificity of CNVs presents problems for their use in diagnosis at present. Currently, there is also insufficient evidence in relation to schizophrenia to suggest that clear clinical benefit would be gained from learning one's genetic status pre-symptomatically. However, this is likely to change rapidly in the near future as knowledge of the genetic and environmental basis of schizophrenia accrues and increasingly effective measures for early intervention and risk reduction are developed.
Collapse
Affiliation(s)
- David A Collier
- Medical Research Council, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's CollegeDe Crespigny Park, Denmark Hill, London SE5 8AFUK
| | - Evangelos Vassos
- Medical Research Council, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's CollegeDe Crespigny Park, Denmark Hill, London SE5 8AFUK
- Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King's CollegeDe Crespigny Park, Denmark Hill, London SE5 8AFUK
| | - Simon Holden
- Department of Clinical Genetics Guy's & St Thomas' NHS Foundation TrustGreat Maze Pond, London SE1 9RTUK
| | - Christine Patch
- Department of Clinical Genetics Guy's & St Thomas' NHS Foundation TrustGreat Maze Pond, London SE1 9RTUK
- Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's CollegeGreat Maze Pond, London SE1 9RTUK
| | - Philip McGuire
- Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King's CollegeDe Crespigny Park, Denmark Hill, London SE5 8AFUK
| | - Cathryn Lewis
- Medical Research Council, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's CollegeDe Crespigny Park, Denmark Hill, London SE5 8AFUK
- Department of Clinical Genetics Guy's & St Thomas' NHS Foundation TrustGreat Maze Pond, London SE1 9RTUK
| |
Collapse
|
19
|
Abstract
Ethical considerations in psychiatric genetics are highly complex and fluid. This review introduces the reader to the wide range of ethical considerations in this field by examining four characteristics of genetic information. First, genetic information may, to a greater or lesser extent, predict a person's future health. Second, learning about one's genotype may have profound psychosocial consequences. Third, genetic information pertains to a person's biological relatives and thus can affect family members, communities, and population groups. Finally, psychiatric genetics is a rapidly evolving field. None of these characteristics is necessarily "exceptional" or unique to genetics, but they provide a useful framework for teasing apart a complex set of ethical considerations. This article reviews conceptual and empirical data that speak to these four characteristics and then presents a set of conceptual frameworks that can be used to systematically analyze the ethics of psychiatric genetic research and clinical genotyping. Finally, directions for future study are described--including the urgent need to gather data on actual risks and benefits of psychiatric genetic research and clinical applications, so that their utility can be assessed and appropriate ethical safeguards identified.
Collapse
Affiliation(s)
- Jinger G Hoop
- Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
| |
Collapse
|